首页 > 市场调查报告书 > 医疗设备

药物递输设备

市场调查报告书

商品编码

1542933

全球给药输液系统市场 - 2024-2031

Global Drug Delivery Infusion System Market - 2024-2031

出版日期: 2024年08月26日 | 出版商:

DataM Intelligence | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

报告概述

全球药物输送输液系统市场将于 2023 年达到 128 亿美元，预计到 2031 年将达到 217 亿美元，2024-2031 年预测期间复合年增长率为 6.8%。

药物输送输注系统是一种医疗设备，旨在以受控和调节的方式将液体、药物和治疗剂直接注射到患者的血液中。这些系统广泛应用于各种医疗保健环境，包括医院、诊所、门诊护理机构和家庭医疗保健。它们对于提供药物和治疗化疗、疼痛管理、胰岛素治疗和抗生素治疗等疾病至关重要。

输液系统由几个关键部件组成，包括药物储存库、推进机构、流量控制器、管道和用于给药的静脉导管。精确控制药物传递的能力对于有效治疗至关重要，特别是对于需要持续药物管理的患者。

市场动态：

司机

慢性病盛行率上升和技术进步

全球给药输液系统市场的需求由多种因素所驱动。推动市场成长的主要驱动力是癌症和糖尿病等慢性疾病的高盛行率，尤其是老年患者，以及不断进步的技术进步。

根据国家卫生中心的数据，2022 年，癌症是全球第二大死因，2022 年新增病例约为 1,918,030 例。此外，根据世界卫生组织的数据，到 2030 年，新病例数预计将增加 70% 左右。

同样，根据世界卫生组织 2022 年的资料，估计有 2,000 万新癌症病例和 970 万人死于该疾病。大约有 5350 万人在被诊断出患有癌症五年后仍然活着。根据统计，大约五分之一的人会在一生中的某个阶段罹患癌症，其中大约九分之一的男性和十二分之一的女性死于这种疾病。

此外，关键参与者的策略（例如伙伴关係和协作以及技术进步）将推动该市场的成长。例如，2023 年 11 月，KORU Medical Systems, Inc. 宣布与生物製药製造商达成新的开发协议。此次合作将专注于创建专为皮下免疫球蛋白（SCIg）治疗而设计的下一代输注系统并获得监管部门的批准。这项措施体现了 KORU Medical 透过创新输液技术改善患者生活品质的承诺。

此外，2023 年 6 月，Eitan Medical 宣布推出 Eitan Insights，这是一款专为家庭和专业输液量身定制的基于云端的新型输液管理系统。该公司的输液系统 Sapphire 现在配备了新型通用即插即用蜂窝配件 Sapphire Connect 和 Avoset（与 AvosetGo 应用程式配合使用），旨在连接输液治疗资料并将其传输到 Eitan Insights。这种整合透过提供即时资料和改善整体患者护理来增强输液治疗的管理。

限制

产品召回、输液系统成本高昂、缺乏熟练的专业人员、严格的监管要求、患者安全问题和输液不当以及报销挑战等因素预计将阻碍市场。

细分市场分析

全球给药输液系统市场根据产品类型、应用、最终用户和地区进行细分。

容量输液帮浦领域约占全球给药输液系统市占率的48.2%

预计容量输液帮浦领域将在预测期内占据最大的市场份额。容积输液帮浦 (VIP) 是一种复杂的医疗设备，旨在以各种流速（从非常慢到非常快）精确、连续地输送液体。

这些帮浦广泛用于医疗保健环境中，以精确控制向患者註射静脉 (IV) 药物、液体、全血和血液製品。 VIP 让医疗保健专业人员能够准确管理关键物质进入患者体内的流量，确保最佳治疗效果并最大限度地降低併发症的风险。

此外，行业产品发布和批准的主要参与者将推动该细分市场的市场成长。例如，2024 年 4 月，Baxter International Inc. 宣布其配备 Dose IQ 安全软体的 Novum IQ 大容量输液帮浦 (LVP) 已获得美国食品药物管理局 (FDA) 的 510(k) 批准。

Novum IQ 输液平台增加了 LVP 模式，该平台已包括带有 Dose IQ 安全软体的百特注射器输液帮浦 (SYR) 和 IQ 企业连接套件，使临床医生能够在各种患者护理环境中操作统一的系统。 Novum IQ LVP 在美国的推出突显了百特致力于输液治疗领域持续创新的决心。

同样，2022 年 3 月，Fresenius Kabi 宣布其无线 Agilia Connect 输液系统已获得美国食品药物管理局 (FDA) 的 510(k) 监管许可。该系统包括 Agilia 容量泵和 Agilia 注射泵，两者都配备了采用 Vigilant Master Med 技术的 Vigilant 软体套件。

此外，关键参与者的策略（例如伙伴关係和协作以及併购）将推动该市场的成长。例如，2022 年 3 月，Ivenix, Inc. 宣布已签署最终协议，将被费森尤斯·卡比 (Fresenius Kabi) 收购。此次收购将把 Ivenix 的先进输液系统与 Fresenius Kabi 的静脉输液和输液治疗产品相结合，为美国医院创建全面的输液产品组合。该交易的收购价格包括 2.4 亿美元的预付款，以及与实现特定商业和营运目标相关的额外里程碑付款。

市场地域占有率

北美约占全球给药输液系统市占率的43.6%

由于糖尿病、癌症和心血管疾病等慢性疾病的盛行率不断上升，北美地区预计将在预测期内占据最大的市场份额，这是推动给药输液系统市场的关键因素。这些疾病通常需要长期治疗和准确的给药，导致对输注系统的需求增加，特别是胰岛素帮浦和化疗输送设备。

输液技术的进步，特别是配备改进的安全功能和连接性的智慧输液帮浦的创建，正在推动市场的成长。这些创新提高了病患安全和治疗效果，使输液系统对医疗保健提供者越来越有吸引力。对北美医疗基础设施的投资增加使得尖端输液系统广泛采用

此外，大量关键参与者的存在、先进的医疗基础设施、产品发布和批准将推动该地区的市场成长。例如，2024 年 5 月，穆格公司的 CURLIN 8000 流动输液系统获得了美国食品药物管理局 (FDA) 的 510(k) 许可，该系统专为家庭输液环境而设计。这种先进的输液平台是一种新型多疗法系统，专为满足家庭护理的独特需求而量身定制。

此外，2023 年 8 月，ICU Medical 宣布美国食品药物管理局 (FDA) 已为其 Plum Duo 输液帮浦和 LifeShield 输液安全软体授予 510(k) 许可。这个新系统将于 2024 年初向美国客户提供，它建立在 ICU Medical 屡获殊荣的 Plum 360 输液泵的精确输送能力的基础上。

同样，2023 年 7 月，BD 宣布其更新的 BD Alaris 输液系统已获得美国食品药物管理局 (FDA) 的 510(k) 批准。此次批准不仅可以修復现有系统，还可以使被认为是美国最全面的输液系统恢復全面商业运作。

A drug delivery infusion system is a medical device designed to administer fluids, medications, and therapeutic agents directly into a patient's bloodstream in a controlled and regulated manner. These systems are widely used across various healthcare environments, including hospitals, clinics, ambulatory care settings, and home healthcare. They are essential for delivering pharmaceuticals and treatments for conditions such as chemotherapy, pain management, insulin therapy, and antibiotic administration.

Infusion systems consist of several key components, including a drug reservoir, a mechanism for propulsion, flow controllers, tubing, and an intravenous catheter for administration. The ability to precisely control the delivery of medications is crucial for effective treatment, particularly for patients who require ongoing medication management.

Market Dynamics: Drivers

Rising prevalence of chronic diseases & technological advancements

The demand for the global drug delivery infusion system market is driven by multiple factors. The major drivers fueling the growth of the market are the high prevalence of cancer and chronic diseases such as diabetes, especially in geriatric patients, and increasing technical advancements.

According to the National Centre for Health, in 2022, cancer was the second leading cause of mortality worldwide, with around 1,918,030 new cases registered in 2022. Cancer was responsible for 609,360 deaths all over the world. Moreover, as per WHO the number of new cases is expected to rise by around 70% by 2030.

Similarly, as per WHO data in 2022, it was estimated that there were 20 million new cancer cases and 9.7 million deaths attributed to the disease. Approximately 53.5 million individuals were alive five years after being diagnosed with cancer. Statistically, about 1 in 5 people will develop cancer at some point in their lives, with roughly 1 in 9 men and 1 in 12 women succumbing to the illness.

Moreover, key player's strategies such as partnerships & collaborations, and technological advancements would drive this market growth. For instance, in November 2023, KORU Medical Systems, Inc. announced a new development agreement with a biopharmaceutical manufacturer. This partnership will focus on creating and obtaining regulatory approval for a next-generation infusion system specifically designed for subcutaneous immunoglobulin (SCIg) therapy. This initiative reflects KORU Medical's commitment to improving patient quality of life through innovative infusion technologies.

Also, in June 2023, Eitan Medical announced the launch of Eitan Insights, a new cloud-based infusion management system tailored for home and specialty infusions. The company's infusion systems, Sapphire now equipped with the new universal plug-and-play cellular accessory Sapphire Connect and Avoset, which works with the AvosetGo app, are designed to connect and transmit infusion treatment data to Eitan Insights. This integration enhances the management of infusion therapies by providing real-time data and improving overall patient care.

Restraints

Factors such as product recalls, the high cost of infusion systems, lack of skilled professionals, stringent regulatory requirements, patient safety concerns & improper infusion, and reimbursement challenges are expected to hamper the market.

Market Segment Analysis

The global drug delivery infusion system market is segmented based on product type, application, end-user, and region.

The volumetric infusion pumps segment accounted for approximately 48.2% of the global drug delivery infusion system market share

The volumetric infusion pumps segment is expected to hold the largest market share over the forecast period. Volumetric infusion pumps (VIPs) are sophisticated medical devices designed to deliver precise and continuous amounts of fluids at a wide range of flow rates, from very slow to very fast.

These pumps are widely used in healthcare settings to precisely control the administration of intravenous (IV) medications, fluids, whole blood, and blood products to patients. VIPs enable healthcare professionals to accurately manage the flow of critical substances into a patient's body, ensuring optimal therapeutic effects and minimizing the risk of complications.

Moreover, key players in the industry product launches and approvals that would propel this segment's growth in the market. For instance, in April 2024, Baxter International Inc. announced that its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

This addition of the LVP modality to the Novum IQ Infusion Platform, which already includes Baxter's syringe infusion pump (SYR) with Dose IQ Safety Software and the IQ Enterprise Connectivity Suite, allows clinicians to operate a unified system across various patient care environments. The introduction of the Novum IQ LVP in the U.S. underscores Baxter's dedication to ongoing innovation in the field of infusion therapy.

Similarly, in March 2022, Fresenius Kabi announced that it had received 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA) for its wireless Agilia Connect Infusion System. This system includes the Agilia Volumetric Pump and the Agilia Syringe Pump, both equipped with the Vigilant Software Suite featuring Vigilant Master Med technology.

In addition, key player's strategies such as partnerships & collaborations and mergers & acquisitions would drive this market growth. For instance, in March 2022, Ivenix, Inc. announced that it had entered into a definitive agreement to be acquired by Fresenius Kabi. The acquisition will combine Ivenix's advanced infusion system with Fresenius Kabi's intravenous fluids and infusion therapy offerings, creating a comprehensive portfolio of infusion products for U.S. hospitals. The deal involves a purchase price that includes an upfront payment of $240 million, along with additional milestone payments tied to the achievement of specific commercial and operational targets.

Market Geographical Share

North America accounted for approximately 43.6% of the global drug delivery infusion system market share

North America region is expected to hold the largest market share over the forecast period owing to the growing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular conditions is a key factor driving the drug delivery infusion system market. These illnesses typically necessitate long-term treatment and accurate drug administration, leading to an increased demand for infusion systems, especially insulin pumps and chemotherapy delivery devices.

Advancements in infusion technology, particularly the creation of smart infusion pumps equipped with improved safety features and connectivity, are driving growth in the market. These innovations enhance patient safety and treatment effectiveness, making infusion systems increasingly attractive to healthcare providers. Increased investments in North America's healthcare infrastructure are enabling the widespread adoption of cutting-edge infusion systems

Moreover, a major number of key player's presence, well-advanced healthcare infrastructure, product launches, and approvals would drive this market growth in this region. For instance, in May 2024, Moog Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its CURLIN 8000 Ambulatory Infusion System, designed specifically for home infusion settings. This advanced infusion platform is a new multi-therapy system tailored to meet the unique demands of home care.

Also, in August 2023, ICU Medical announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Plum Duo infusion pump and LifeShield infusion safety software. This new system, which will be available to U.S. customers in early 2024, builds upon the precise delivery capabilities of ICU Medical's award-winning Plum 360 infusion pump.

Similarly, in July 2023, BD announced that its updated BD Alaris Infusion System had received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This approval allows for both the remediation of existing systems and a return to full commercial operations for what is considered the most comprehensive infusion system available in the United States.

Market Segmentation

By Product Type

Volumetric Infusion Pumps
Syringe Infusion Systems
Ambulatory Infusion Systems
Implantable Infusion Systems
Insulin Infusion Pumps
Enteral Infusion Systems
Large Volume Infusion Systems
Patient Controlled Analgesia (PCA)
Elastomeric Infusion Pumps

By Application

Oncology/Chemotherapy
Diabetes
Analgesia
Nutrition
Hematology
Pediatrics
Others

By End-User

Hospitals
Specialty Clinics
Ambulatory Surgery Centers
Homecare Settings

By Region

North America
- The U.S.
- Canada
- Mexico
Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
South America
- Brazil
- Argentina
- The rest of South America
Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Middle East and Africa

Market Competitive Landscape

The major global players in the drug delivery infusion system market include Medtronic, Eitan Medical, B. Braun SE, BD, Baxter, Terumo Corporation, Insulet Corporation., Fresenius Kabi AG, Arcomed, and ICU Medical, Inc. among others.

Key Developments

In January 2024, AbbVie introduced PRODUODOPA (foslevodopa/foscarbidopa) in the European Union, marking it as the first and only subcutaneous infusion therapy that provides continuous 24-hour delivery of levodopa for individuals with advanced Parkinson's disease.
In December 2023, TriSalus Life Sciences Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has established a new Healthcare Common Procedure Coding System (HCPCS) code for procedures involving the company's TriNav infusion system.
In June 2023, B. Braun launched its latest infusion management software, DoseTrac Enterprise, which provides organizations with a combination of real-time monitoring and historical reporting capabilities to gain deeper insights into their infusion pump fleet and related data. This new software platform enables healthcare providers to better comprehend and optimize their infusion pump infrastructure by offering a blend of live data visualizations and in-depth retrospective analytics.
In April 2023, Eitan Medical announced the launch of its innovative Avoset-connected infusion system, a multi-therapy ambulatory infusion pump designed to revolutionize post-acute care and specialty infusion therapy. This advanced system features compact and user-friendly technology that allows for remote monitoring of infusion treatment data, enhancing patient safety and improving the overall user experience.
In February 2023, Mindray introduced its BeneFusion i Series and u Series infusion systems, designed to enhance medication safety across various clinical environments. These systems feature high precision, adaptive customization, and user-friendly interfaces, ensuring reliable medication delivery.

Why Purchase the Report?

To visualize the global drug delivery infusion system market segmentation based on product type, application, end-user, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the drug delivery infusion system market with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.

The global drug delivery infusion system market report would provide approximately 62 tables, 63 figures, and 183 pages.

Target Audience 2024

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Application
3.3. Snippet by End-User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising Prevalence of Chronic Diseases & Technological Advancements
- 4.1.2. Restraints
  - 4.1.2.1. Product Recalls
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. By Product Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Volumetric Infusion Pumps
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Syringe Infusion Systems
6.4. Ambulatory Infusion Systems
6.5. Implantable Infusion Systems
6.6. Insulin Infusion Pumps
6.7. Enteral Infusion Systems
6.8. Large Volume Infusion Systems
6.9. Patient Controlled Analgesia (PCA)
6.10. Elastomeric Infusion Pumps

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application
7.2. Oncology/Chemotherapy *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Diabetes
7.4. Analgesia
7.5. Nutrition
7.6. Hematology
7.7. Pediatrics
7.8. Others

8. By End-User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Specialty Clinics
8.4. Ambulatory Surgery Centers
8.5. Homecare Settings

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. The U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. U.K.
  - 9.3.6.3. France
  - 9.3.6.4. Spain
  - 9.3.6.5. Italy
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. South Korea
  - 9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Medtronic*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Eitan Medical
11.3. B. Braun SE
11.4. BD
11.5. Baxter
11.6. Terumo Corporation
11.7. Insulet Corporation.
11.8. Fresenius Kabi AG
11.9. Arcomed
11.10. ICU Medical, Inc. (*LIST NOT EXHAUSTIVE)